Antigens, CD19

"Antigens, CD19" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.

Descriptor ID

D018941

MeSH Number(s)

D23.050.301.264.035.119

D23.050.301.264.051.119

D23.101.100.110.119

D23.101.100.150.119

Concept/Terms

Antigens, CD19

Below are MeSH descriptors whose meaning is more general than "Antigens, CD19".

Chemicals and Drugs [D]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Antigens, Differentiation [D23.050.301.264]
Antigens, CD [D23.050.301.264.035]
Antigens, CD19 [D23.050.301.264.035.119]
Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
Antigens, CD19 [D23.050.301.264.051.119]
Biological Markers [D23.101]
Antigens, Differentiation [D23.101.100]
Antigens, CD [D23.101.100.110]
Antigens, CD19 [D23.101.100.110.119]
Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
Antigens, CD19 [D23.101.100.150.119]

Below are MeSH descriptors whose meaning is related to "Antigens, CD19".

Below are MeSH descriptors whose meaning is more specific than "Antigens, CD19".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antigens, CD19" by people in Harvard Catalyst Profiles by year, and whether "Antigens, CD19" was a major or minor topic of these publication.

Bar chart showing 215 publications over 30 distinct years, with a maximum of 28 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	2	2
1996	1	1	2
1997	1	1	2
1998	1	1	2
1999	1	2	3
2000	3	3	6
2001	1	3	4
2002	0	2	2
2003	0	3	3
2004	1	0	1
2005	1	4	5
2006	0	3	3
2007	1	1	2
2008	1	3	4
2009	2	4	6
2010	1	0	1
2011	1	4	5
2012	0	3	3
2013	2	4	6
2014	0	4	4
2015	3	7	10
2016	0	2	2
2017	7	7	14
2018	6	2	8
2019	8	7	15
2020	18	7	25
2021	10	13	23
2022	1	27	28
2023	0	21	21
2024	0	3	3

Below are the most recent publications written about "Antigens, CD19" by people in Profiles.

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May; 99(5):880-889.

View in: PubMed
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024 Feb 08; 143(6):496-506.

View in: PubMed
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 2024 Mar; 59(3):366-372.

View in: PubMed
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy. Haematologica. 2023 Dec 01; 108(12):3433-3437.

View in: PubMed
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy. Haematologica. 2023 11 01; 108(11):2972-2981.

View in: PubMed
Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy. Hematol Oncol. 2024 Jan; 42(1):e3221.

View in: PubMed
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement. Br J Haematol. 2023 12; 203(5):774-780.

View in: PubMed
Low Pretreatment CD4+:CD8+ T Cell Ratios and CD39+CD73+CD19+ B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2023 Aug 08; 24(16).

View in: PubMed
A stem cell epigenome is associated with primary nonresponse to CD19 CAR T cells in pediatric acute lymphoblastic leukemia. Blood Adv. 2023 08 08; 7(15):4218-4232.

View in: PubMed
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. J Immunother Cancer. 2023 08; 11(8).

View in: PubMed

Related Networks

People

Explore

Similar Concepts

Top Journals

Blood
J Immunol
N Engl J Med
Blood Adv
Immunity
Leuk Lymphoma
J Immunother Cancer
Nat Med
Lancet
J Allergy Clin Immunol